Compounds › Combinations

Wolverine

BPC-157 + TB-500, the repair base

Not approvedCombinations

Experimental material. Read before using anything from here.

Nothing on this page is a medical recommendation, prescription or treatment plan. It is an organized translation of protocols circulating in research communities and, where it exists, of what published trials tested. The two are marked differently — and they are not equivalent.

Most of the compounds here have no FDA approval for human use. Several are sold labeled "research use only", which means they have not gone through purity, sterility or dosage controls for human consumption. A community-reported dose is not a validated dose: it is what someone reported having done.

Talk to a licensed health professional before considering any of these compounds. If you already use one and feel anything unexpected, seek care — do not wait for the next routine test.

Summary

Community nickname for the BPC-157 + TB-500 pair in a protocol focused on tissue repair. The name comes from the comic-book character known for fast healing — and is not a description of what the pair does. It is the simplest base: GLOW and KLOW are it with additions.

Quick reference

Compounds: BPC-157 + TB-500, often in a 1:1 pre-mixed 20 mg vial.
Schedule: Daily draws from the blend, or daily BPC-157 + TB-500 2×/week in separate vials.
Reconstitution: 2.0 mL of bacteriostatic water in a 20 mg blend → 10 mg/mL in total (5 mg/mL of each).
Cycle: Most protocols run 6–12 weeks in total, generally loading + maintenance.

Wolverine Stack Dosage and Frequency at a Glance

Total Daily Blend	BPC-157 Amount	TB-500 Amount	Common frequency	Units From 20 mg Vial + 2 mL
0.5 mg total	250 mcg	250 mcg	Commonly described as daily	5 units
1.0 mg total	500 mcg	500 mcg	Commonly described as daily	10 units
1.5 mg total	750 mcg	750 mcg	Community reference only	15 units
2.0 mg total	1 mg	1 mg	Community reference only	20 units

Pre-blended Vial vs Separate Vials: Which Format Fits the Plan

Factor	Pre-blended 1:1 vial	Separate vials
Daily injection burden	1 injection (combined)	1–2 injections (depending on day)
Dose control	Locked at 1:1 BPC-157 : TB-500	Independent BPC-157 and TB-500 doses
Schedule control	Both compounds on the same schedule	BPC-157 daily + TB-500 2x/week, etc.
TB-500 weekly exposure (typical)	1.25–7.0 mg/week (steady, daily)	4.0–10.0 mg/week (pulsed, 2x/week loading)
Reconstitution complexity	One vial	Two vials, two reconstitution steps
Best for	Simplicity, steady exposure	Injury-focused planning, dose tuning

Wolverine Stack Reconstitution and Syringe Units

Blend Vial	Example BAC Water	Total Concentration	5 Units Delivers	10 Units Delivers
10 mg total: 5 mg + 5 mg	1 mL	10 mg/mL total	0.5 mg total	1 mg total
10 mg total: 5 mg + 5 mg	2 mL	5 mg/mL total	0.25 mg total	0.5 mg total
20 mg total: 10 mg + 10 mg	2 mL	10 mg/mL total	0.5 mg total	1 mg total
20 mg total: 10 mg + 10 mg	3 mL	About 6.67 mg/mL total	About 0.33 mg total	About 0.67 mg total

Reconstitution by Format

Spec	Value
Vial size	20 mg total (10 mg BPC-157 + 10 mg TB-500)
BAC water added	2.0 mL
Total concentration	10 mg/mL (5 mg/mL each compound)
10 units (0.10 mL) delivers	0.5 mg BPC-157 + 0.5 mg TB-500
20 units (0.20 mL) delivers	1.0 mg BPC-157 + 1.0 mg TB-500
Doses per vial (1.0 mg/day)	~20 days

Reconstitution by Format

Spec	BPC-157 (10 mg vial)	TB-500 (10 mg vial)
BAC water added	2.0 mL	2.0 mL
Final concentration	5.0 mg/mL	5.0 mg/mL
10 units (0.10 mL) delivers	500 mcg	500 mcg
20 units (0.20 mL) delivers	1.0 mg	1.0 mg
Doses per vial (typical)	~20–40 days	~4–5 loading doses

Wolverine Stack Cycle Length: 6–12 Week Community Schedules

Approach	Loading	Maintenance	Total cycle	Common context
Pre-blended daily	—	0.5–2.0 mg total blend daily	6–12 weeks	Convenience-first, steady exposure
Separate vials standard	Weeks 1–4	Weeks 5-8	8–12 weeks	Loading-then-taper for injury planning
Separate vials extended	Weeks 1–4	Weeks 5-12	12 weeks	Slower-healing tissue research planning

Wolverine Stack vs Single Compounds vs Other Healing Stacks

Stack / compound	Compounds	Main research focus	Format note
Wolverine Stack	BPC-157 + TB-500	Soft-tissue / tendon / systemic repair	1:1 pre-blend or separate vials
BPC-157 alone	BPC-157	Local injury site, gut	Single 5 mg vial typical
TB-500 alone	TB-500 (Tβ4 fragment)	Systemic mobility, cardiac (preclinical)	Single 10 mg vial typical
GLOW Stack	BPC-157 + TB-500 + GHK-Cu	Adds skin/connective-tissue layer	Often blended vial
KLOW Stack	BPC-157 + TB-500 + GHK-Cu + KPV	Adds inflammation/gut layer	Usually separate or part-blended

KPV Cycle Length Chart

Cycle length	How it is usually described	Evidence note
4-6 weeks	Short focused cycle or early loading-only plan	Common in community discussions; not tested as a combined clinical protocol
6–8 weeks	Most common full cycle with loading and maintenance phases	Community standard; no controlled human trial
8–12 weeks	Extended plan for slower or longer research timelines	Less consistent and supported by even less safety data
More than 12 weeks	Long-term or repeated use	No established human safety basis for the combined stack

Pre-Blended vs Separate-Vial Cycles

Format	Common schedule pattern	Main limitation
Pre-blended 1:1 vial	One combined draw on a regular schedule across the cycle	The dose ratio stays fixed, so one compound cannot be changed without changing the other
Separate BPC-157 and TB-500 vials	Daily BPC-157 with less frequent TB-500, often followed by a lower-frequency phase	More complex math and more chances for schedule errors

Storage and handling

The rules below apply to practically every lyophilized peptide in this reference. Where a compound has its own requirement, it appears in the table in the previous section.

Lyophilized powder, sealed: refrigerator, between 2 and 8 °C, protected from light. Many tolerate room temperature for short transport periods, but that is tolerance, not a recommendation.
After reconstitution: always refrigerated, between 2 and 8 °C. The stability window drops to days or a few weeks, depending on the compound.
Never freeze after reconstituting. The freeze–thaw cycle degrades the peptide.
Do not shake. Swirl the vial slowly. Shaking breaks the peptide chain.
Bacteriostatic water down the wall of the vial, in a slow stream, not squirted directly onto the powder.
Cloudy solution, with particles or a color change: discard. There is no recovery.

Lab tests and monitoring

This list is the one that appears recurrently in the source, with small variations by compound. It serves as a starting point for a conversation with a professional — not as a substitute for that conversation.

Before starting: complete blood count, comprehensive metabolic panel, lipid panel, fasting glucose and HbA1c, TSH and free T4, blood pressure and resting heart rate.
Depending on the compound: IGF-1 (GH axis), lipase and amylase (VIP and the incretin agonists), serum copper and ceruloplasmin (GHK-Cu and blends containing it), CRP.
Reassessment: most protocols review between week 4 and week 8, and then every 8–12 weeks.
Do not wait for the routine lab test in the face of abdominal pain, visual changes, a change in a mole, shortness of breath, asymmetric swelling or any new and persistent symptom. That is a reason to seek care, not a spreadsheet item.

Evidence limits

What these numbers are and what they are not. The values above were preserved exactly as they appear in the source, without reinterpretation. What the source describes as community practice is marked as such in the tables; what came from a published trial is too. A dose repeated by many people does not become a validated dose by repetition.

Data source: peptidedosingprotocols.com, accessed on September 3, 2026. Translation and organization in Portuguese are original work. No primary source (PubMed, trial registry, package insert) was checked in building this page — the check was against the secondary source, and that alone.

← Back to all compounds